Advanced search
Publication Cover
Expert Opinion on Therapeutic Patents Volume 22, 2012 - Issue 8
Submit an article Journal homepage
206
Views
1
CrossRef citations to date
0
Altmetric
Patent Evaluations

Evaluation of WO2012037204 and WO2012037226: Exelixis' selective PI3Kδ inhibitors; the basis of a US$251 million deal

Peter NormanNorman Consulting, 18 Pink Lane, Burnham, Bucks SL1 8JW, UK, [email protected]
, MBA PhD
Pages 971-976 | Published online: 06 Jul 2012

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.